- Home
- NOM vs IGC Comparison
NOM vs IGC Comparison
Compare NOM & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOM
- IGC
- Stock Information
- Founded
- NOM 1993
- IGC 2005
- Country
- NOM United States
- IGC United States
- Employees
- NOM N/A
- IGC N/A
- Industry
- NOM Investment Managers
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- NOM Finance
- IGC Health Care
- Exchange
- NOM Nasdaq
- IGC Nasdaq
- Market Cap
- NOM 25.0M
- IGC 20.2M
- IPO Year
- NOM N/A
- IGC N/A
- Fundamental
- Price
- NOM $10.30
- IGC $0.31
- Analyst Decision
- NOM
- IGC Strong Buy
- Analyst Count
- NOM 0
- IGC 2
- Target Price
- NOM N/A
- IGC $3.88
- AVG Volume (30 Days)
- NOM 6.9K
- IGC 232.1K
- Earning Date
- NOM 01-01-0001
- IGC 08-07-2025
- Dividend Yield
- NOM 3.39%
- IGC N/A
- EPS Growth
- NOM N/A
- IGC N/A
- EPS
- NOM N/A
- IGC N/A
- Revenue
- NOM N/A
- IGC $1,271,000.00
- Revenue This Year
- NOM N/A
- IGC $15.26
- Revenue Next Year
- NOM N/A
- IGC $3.41
- P/E Ratio
- NOM N/A
- IGC N/A
- Revenue Growth
- NOM N/A
- IGC N/A
- 52 Week Low
- NOM $8.52
- IGC $0.25
- 52 Week High
- NOM $10.48
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- NOM 43.02
- IGC 44.22
- Support Level
- NOM $10.32
- IGC $0.30
- Resistance Level
- NOM $10.37
- IGC $0.32
- Average True Range (ATR)
- NOM 0.06
- IGC 0.01
- MACD
- NOM -0.01
- IGC -0.00
- Stochastic Oscillator
- NOM 30.56
- IGC 0.00
About NOM Nuveen Missouri Quality Municipal Income Fund
Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in United States. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Missouri state income taxes; its secondary investment objective is the enhancement of portfolio value. The fund invests in municipal securities as well as floating rate securities as well as derivatives such as futures, options and swap contracts to the necessary extent. Nuveen Fund Advisors, LLC acts as an investment adviser of the company.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.